Roche Holding AG (SWX:ROG)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 239.40B |
| Revenue (ttm) | 62.40B |
| Net Income (ttm) | 8.28B |
| Shares Out | 795.40M |
| EPS (ttm) | 10.31 |
| PE Ratio | 28.94 |
| Forward PE | 14.29 |
| Dividend | 9.70 (3.28%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 1,864,475 |
| Average Volume | 1,198,994 |
| Open | 293.50 |
| Previous Close | 295.30 |
| Day's Range | 292.80 - 298.40 |
| 52-Week Range | 212.90 - 298.40 |
| Beta | 0.18 |
| RSI | 72.89 |
| Earnings Date | Jan 31, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial StatementsNews
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
Basel, 20 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) unveiled today its proprietary, breakthrough sequencing by expansion (SBX) technology, establishing a new category of next-generation seque...
Roche goes beyond diagnostics innovation and builds partnerships for proactive healthcare
[The content of this article has been produced by our advertising partner.] As the global healthcare landscape evolves, coupled with the strains an ageing population exerts on healthcare systems, shif...
Yemaachi Biotechnology Launches The African Cancer Atlas, in Partnership with Roche
ACCRA, Ghana & WASHINGTON--(BUSINESS WIRE)-- #cancerresearch--Yemaachi Biotech, a pioneering genomics research company based in Ghana, announced today a partnership with Roche to launch The African Ca...
Roche upgraded by UBS to buy on growth outlook
FDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
Basel, 12 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam) tab...
FDA Approves Genentech's Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New D...
New England Journal of Medicine publishes new data for Roche's Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis
Basel, 7 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus neph...
New England Journal of Medicine Publishes New Data for Genentech's Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of its Phase III REGENCY trial of Gazyva® (o...
Roche's Susvimo gets FDA approval for diabetic macular edema
Roche's (RHHBY) Genentech unit has received FDA approval for its eye drug Susvimo 100 mg/mL injection for the treatment of diabetic macular edema. Read more here.
FDA Approves Genentech's Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
– Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) – – With as few as two treatments per year, Sus...
FDA approves Roche's Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of...
FDA Approves Genentech's Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo®...
Roche Q4 Earnings Review: Solid All-Court Performance, But Quiet On GLP-1 Progress
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
Basel, 31 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® anti-HER2/neu (4B5) Rabbit ...
Roche Holding AG 2024 Q4 - Results - Earnings Call Presentation
Roche Holding AG (RHHBY) Q4 2024 Earnings Call Transcript
Roche CEO: We had a strong 2024 and expect momentum to carry into 2025
Thomas Schinecker, the CEO of Roche, discusses the Swiss company's full-year earnings.
We had a strong 2024 and expect momentum to carry into 2025, says Roche CEO
Thomas Schinecker, the CEO of Roche, discusses the Swiss company's full-year earnings.
Roche Expects Sales, Earnings Growth After Better-Than-Expected Results
Roche Holding Non-GAAP EPS of CHF 18.80, revenue of CHF 60.49B
Roche sees high single-digit core profit growth in 2025
Swiss drugs and diagnostics company Roche said on Thursday it is targeting an increase in core 2025 earnings per share in a high single-digit percentage range, when adjusted for currency swings.
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
Basel, 30 January 2025 Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics. Excluding COVID-19, Group sales increased by 9%.
Change to the Roche Enlarged Corporate Executive Committee
Basel, 29 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas S...
Genentech's Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
– Updated overall survival (OS) results – a key secondary endpoint – reinforce the significant benefit of the Itovebi TM (inavolisib)-based regimen for patients with advanced PIK3CA-mutated, HR-positi...
Roche's Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer
Basel, 28 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from the overall survival (OS) analysis of the phase III INAVO120 study investigating ItovebiTM (in...